SCHEMBL21859000

SCHEMBL21859000

CCOC(=O)/C(=C\N(C)C)C(=O)c1cc(Cl)nnc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.41
CASP1 P29466 2/20 0.39
ALDH1A1 P00352 6/20 0.36
NPSR1 Q6W5P4 4/20 0.36
LMNA P02545 4/20 0.36
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
MAPT P10636 5/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ATM Q13315 1/20 0.35
HPGD P15428 4/20 0.34
KDM4E B2RXH2 1/20 0.34
NPY1R P25929 1/20 0.34
NPY2R P49146 1/20 0.34
GLO1 Q04760 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
S1PR4 O95977 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21859001 1.00 CYP2C9 (0.41) CYP2C9CASP1ALDH1A1NPSR1LMNA
SCHEMBL3289090 0.82 NPSR1 (0.40) CYP2C9ALDH1A1NPSR1LMNAMEN1
SCHEMBL29980176 0.82 NPSR1 (0.45) CYP2C9ALDH1A1NPSR1MEN1KMT2A
SCHEMBL3289092 0.82 NPSR1 (0.40) CYP2C9ALDH1A1NPSR1LMNAMEN1
SCHEMBL4161766 0.82 NPSR1 (0.40) CYP2C9ALDH1A1NPSR1LMNAMEN1
SCHEMBL19987092 0.82 NPSR1 (0.45) CYP2C9ALDH1A1NPSR1MEN1KMT2A
SCHEMBL21174039 0.82 NPSR1 (0.45) CYP2C9ALDH1A1NPSR1MEN1KMT2A
SCHEMBL13756506 0.81 KEAP1 (0.44) CYP2C9ALDH1A1NPSR1LMNAMEN1
SCHEMBL9562369 0.81 KEAP1 (0.44) CYP2C9ALDH1A1NPSR1LMNAMEN1
SCHEMBL31696352 0.81 KEAP1 (0.44) CYP2C9ALDH1A1NPSR1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214998-A1 CYCLIC COMPOUNDS AS RECEPTOR MODULATING THERAPEUTICS AND METHODS AND USES THEREOF BIONOMICS LTD (AU) 2025-07-03 US disclosed
US-12275732-B2 Cyclic compounds as receptor modulating therapeutics and methods and uses thereof BIONOMICS LIMITED (AU) 2025-04-15 US disclosed
EP-3867252-B1 6-INDAN-2-YLOXY-3-(MORPHOLINE-4-CARBONYL)-1,8-NAPHTHYRIDIN-4-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS MODULATORS OF THE ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR FOR THE TREATMENT OF ANXIETY BIONOMICS LTD (AU) 2023-12-06 EP disclosed
US-20210355124-A1 Cyclic compounds as receptor modulating therapeutics and methods and uses thereof BIONOMICS LIMITED (AU) 2021-11-18 US disclosed
US-20210355124-A1 Cyclic compounds as receptor modulating therapeutics and methods and uses thereof BIONOMICS LIMITED (AU) 2021-11-18 US disclosed
WO-2020077414-A1 CYCLIC COMPOUNDS AS RECEPTOR MODULATING THERAPEUTICS AND METHODS AND USES THEREOF BIONOMICS LIMITED (AU) 2020-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214998-A1 CYCLIC COMPOUNDS AS RECEPTOR MODULATING THERAPEUTICS AND METHODS AND USES THEREOF CHRNA7, CHRNA5, CHRNA1 CYP2C9 1995/4885CASP1 4454/4885ALDH1A1 836/4885
US-12275732-B2 Cyclic compounds as receptor modulating therapeutics and methods and uses thereof CHRNA7, CHRNA1, CHRNA5 CYP2C9 1938/4885CASP1 4402/4885ALDH1A1 832/4885
US-20210355124-A1 Cyclic compounds as receptor modulating therapeutics and methods and uses thereof CHRNA7, CHRNA1, CHRNA5 CYP2C9 1938/4885CASP1 4402/4885ALDH1A1 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.